Assessing infection and inflammation in people with cystic fibrosis using their breath: a pilot longitudinal study
Open Access
- 16 November 2026
- journal article
- Published by IOP Publishing in Journal of Breath Research
- Vol. 20 (4) , 046014
Abstract
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have revolutionized cystic fibrosis (CF) management, but airway infections and inflammation persist. This study evaluates longitudinal exhaled breath profiles and identifies volatile organic compounds (VOCs) that correlate with sputum bacterial load and neutrophil elastase (NE) levels during ivacaftor and/or antibiotic treatment. Eight people with CF (pwCF) with a heterozygous R117H CFTR mutation and chronic lung infection with P. aeruginosa ( Pa ) and/or S. aureus (Sa) were enrolled in a longitudinal study at St. Vincent’s University Hospital in Dublin, Ireland. Breath samples and sputum samples were collected at multiple time points. Correlation analyses were performed between VOC abundances and bacterial load or NE levels. We observed temporal changes in breath profile across the eight subjects during the ivacaftor and/or antibiotic treatment. Within Pa -infected subjects, 54 VOCs showed consistent directional Pearson correlation and at least moderate repeated measures correlation (rmcorr) coefficient ( r rm ) with bacterial load, including the 12 VOCs previously reported as Pa -associated markers. Similarly, within Sa- infected subjects, we identified eight VOCs that showed consistent directional correlation and at least moderate r rm with bacterial load, including four previously reported Sa -associated markers. Additionally, we identified 7 exploratory VOC candidates that consistently correlated with changes in NE levels, each demonstrating agenerally weak r rm across eight subjects. This study demonstrates that breath profiles of pwCF change over time during ivacaftor and/or antibiotic treatment. Identifying specific breath VOCs whose levels correlate with Pa or Sa CFU/ml, as well as NE levels, supports further evaluation of exhaled breath VOCs as non-invasive markers for monitoring airway infection and inflammation in pwCF.Keywords
Funding Information
- Canada Research Chairs (CRC-2020-00151)
- Cystic Fibrosis Foundation (SINGH18G0)
- National Institutes of Health (R01HL148274)
- Vertex, Inc.
This publication has 83 references indexed in Scilit:
- Modeling reciprocal adaptation of Staphylococcus aureus and Pseudomonas aeruginosa co-isolates in artificial sputum mediumBiofilm, 2025
- Structural analysis of ExaC, an NAD+-dependent aldehyde dehydrogenase, from Pseudomonas aeruginosaBiochemical and Biophysical Research Communications, 2024
- Mucus obstruction and inflammation in early cystic fibrosis lung disease: Emerging role of the IL‐1 signaling pathwayPediatric Pulmonology, 2019
- Aldehyde dehydrogenase diversity in bacteria of the Pseudomonas genusChemico-Biological Interactions, 2019
- Neutrophil elastase correlates with increased sphingolipid content in cystic fibrosis sputumPediatric Pulmonology, 2018
- Quantification of methyl thiocyanate in the headspace of Pseudomonas aeruginosa cultures and in the breath of cystic fibrosis patients by selected ion flow tube mass spectrometryRapid Communications in Mass Spectrometry, 2011
- Hydrogen cyanide as a biomarker for Pseudomonas aeruginosa in the breath of children with cystic fibrosisPediatric Pulmonology, 2009
- The analysis of 1‐propanol and 2‐propanol in humid air samples using selected ion flow tube mass spectrometryRapid Communications in Mass Spectrometry, 2005
- Detection of volatile compounds emitted byPseudomonas aeruginosa using selected ion flow tube mass spectrometryPediatric Pulmonology, 2005
- Genetics of alkane oxidation byPseudomonas oleovoransBiodegradation, 1994